Latigo Biotherapeutics, Inc.
corporate_fare Company Profile
Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 6 items for LTGO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-03, rated 8/10. Across its 6 most recent items scored 7 or higher, the top rating is 8/10, with 3 rated 8 or above. Recent SEC coverage for LTGO spans 10-Q, 8-K, SCHEDULE 13D, 4.
Recent high-impact activity:
- Latigo 10-Q Reveals Material Weakness in Internal Controls Alongside Q2 Loss and IPO Details
- Latigo Biotherapeutics Posts $27.59 Q2 Loss Per Share
- Latigo Reports Q2 Loss of $25.8M, NEJM Publication, and Cash Runway into 2029
- Foresite Capital Reveals 14.5% Stake in Latigo Biotherapeutics After IPO
- Director James Tananbaum Invests $2.52M in Latigo Biotherapeutics at the IPO Price
Short Interest & Short Volume
2.11 days to coverFINRA reported short interest of 449,962 shares in LTGO as of the September 15, 2026 settlement, a 45.8% increase from the prior period — about 2.1 days to cover at its recent average daily volume. On October 2, 2026, 84.8% of LTGO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.